Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

...

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

Research findings may help scientists develop anthrax treatments for humans

Researchers at the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, both part of the National Institutes of Health, have identified the cells in two distinct areas of the body that are simultaneously targeted for damage by anthrax toxins, eventually causing illness and sometimes death. Their findings, which appeared online today in Nature, are based on testing in mice.

29 Aug 2013

Risk factors linked to death may be reversible in severe encephalitis patients

People with severe encephalitis - inflammation of the brain - are much more likely to die if they develop severe swelling in the brain, intractable seizures or low blood platelet counts, regardless of the cause of their illness, according to new Johns Hopkins research.

21 Aug 2013

New data analyzing technique via MR imaging identify tumors' response to anti-angiogenesis therapy

A new way of analyzing data acquired in MR imaging appears to be able to identify whether or not tumors are responding to anti-angiogenesis therapy, information that can help physicians determine the most appropriate treatments and discontinue ones that are ineffective.

20 Aug 2013

Study: H3 receptor antagonist can improve brain edema in adult hypoxic rats

Thioperamide, a selective histamine H3 receptor antagonist, can increase histamine content in the brain and improve brain edema in adult hypoxic rats. Brain edema is precisely considered as the important pathological change of neonatal hypoxic-ischemic encephalopathy.

13 Aug 2013

Harvard University receives grant to use organs-on-chips device to test human response to radiation

A team at the Wyss Institute for Biologically Inspired Engineering at Harvard University has received a $5.6 million grant award from the United States Food and Drug Administration (FDA) to use its Organs-on-Chips technology for a novel application of keen interest to national security and health officials: to test human physiological responses to radiation, and to evaluate drugs designed to counter those effects.

13 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

Chemicals added to swimming pool water can cause irritation, injury and even death, doctors warn

Chemicals are added to swimming pool water to enhance and protect the water quality and minimize disease-causing germs, but these same chemicals can cause irritation, injury and even death when not handled appropriately, doctors at Vanderbilt University Medical Center warn.

1 Aug 2013

Patients with melanoma brain metastases can be treated with large doses of interleukin-2

In a retrospective study, Saint Louis University researchers have found that patients with melanoma brain metastases can be treated with large doses of interleukin-2 (HD IL-2), a therapy that triggers the body's own immune system to destroy the cancer cells.

31 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Study shows lymphatic circulatory system may be intimately involved in vascular disorders

The often forgotten lymphatic circulatory system may be intimately involved in vascular disorders, according to a study by researchers from The University of Texas Health Science Center at Houston (UTHealth) and University of Michigan. Their research was reported recently in the Proceedings of the National Academy of Sciences.

30 Jun 2013

Healthy man injured severely while weight lifting required surgery

A young, healthy man injured himself so severely while weight lifting that he required surgery and nearly a full week in the hospital to recover. The unusual case report of compartment syndrome to the shoulder will be reported online today in Annals of Emergency Medicine ("An Unusual Complication of Weightlifting: A Case Report").